TCT-690 A new method to select device size for atrial septal defect closure based on the largest defect diameter and area on real time three-dimensional transesophageal echocardiography.  by Pedra, Carlos et al.
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PM
P
O
S
T
E
R
STCT-689
Percutaneous Closure Of The Left Atrial Appendage: Initial Experience In Latin
America
Anibal A. Damonte1, Costantino Costantini2, Carlos Pedra3,
Alejandro Martínez Sepúlveda4, Daniel Aguirre5, Fabio Brito6, Jose Condado7,
Fernando Cura8, Leon Valdivieso9, Leandro I. Lasave1
1Instituto Cardiovascular de Rosario, Rosario, Argentina, 2Hospital Cardiologico
costantini, Curitiba, Brazil, 3Instituto Dante Pazzanese, São Paulo, Brazil, 4Hospital
Clínico Pontiﬁcia Universidad Católica de Chile, Santiago, Chile, 5Hospital de Niños
Roberto del Río, Santiago, Chile, 6Hospital Albert Einstein, São Paulo, Brazil, 7centro
medico de caracas, Caracas, Venezuela, 8ICBA, Buenos Aires, Buenos Aires,
9Fundación Favaloro, CABA, Argentina
Background: Atrial ﬁbrillation (AF) is the most common cardiac arrhythmia and
a major cause of morbidity and mortality secondary to cardioembolic stroke. Percu-
taneous closure of the left atrial appendage (LAA) has emerged as an alternative to
anticoagulation therapy for the prevention of cerebrovascular events in patients with
AF and a contraindication or difﬁculties for oral anticoagulation. This study describes
the feasibility, in hospital and follow up results of the transcatheter closure of the LAA
with the Amplatzer Cardiac Plug(ACP; StJude,Minneapolis; MN) in an initial Latin
American experience.
Methods: Physician initiated voluntary registry, including 60 consecutive patients
with AF at high risk for cardioembolic stroke, from different Latin American hospitals
that were treated with the ACP, from August 2009 to June 2012. The procedures were
performed under general anesthesia, transesophageal ecocardiography (TEE) and
ﬂuoroscopic guidance. Clinical and TEE follow up was performed at 30 days, and
clinical follow up thereafter.
Results: 60 patients were included. Age 728.7 years;male70%; hyper-
tensive78%;congestive heart failure32.17%; CHADS2 score 3.151.1; contraindica-
tions to oral anticoagulation 64.3% LAA neck diameter was 20.33.8 mm by TEE
and 22.63.2 by angiography. LAA occlusion was attempted and successfully ach-
ieved in all 60 patients, and in 3 cases, simultaneous closure of the LAA and PFO was
performed. The implanted device size was 252.9 mm. There were serious in hospital
complications in 5 patients (8.3%). 1 patient experienced device embolization that
required surgical retrieval, and 4 (6.6%) patients presented severe pericardial effusion
(SPE) requiring pericardiocentesis. For patients with (SPE) hospitalization was longer
4.251.25, vs 2.772.10 days for patients without SPE p¼0.174. There were not in
hospital deaths, stroke, or myocardial ischemia. No new events were reported at 30
days clinical follow up. 88% of patients underwent TEE at 30-45 days without
evidence of ﬂow to the LAA or thrombus on device. Median follow up was 12.5
months, without strokes.
Conclusions: In this initial experience, percutaneous closure of the LAA with the
ACP in patients with AF at high risk of stroke, was feasible, with a high technical
success and in hospital complications rate similar to previous reports with these and
other devices during the learning phase of the procedure. The results at follow up are
encouraging.
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Background: Device selection for percutaneous atrial septal defect (ASD) closure is
usually based on balloon sizing (BS) of the defect. This step is crucial to avoid under
or oversizing and resultant complications. Although three-dimensional (3D) trans-
esophageal echocardiography (TEE) has been used to guide the procedure, its role in
determining accurate device selection remains an open area for research. We studied
the use of 3D TEE as a possible surrogate for BS for proper device selection in ASD
closure.
Methods: Patients underwent percutaneous ASD closure under general anesthesia
and 3D TEE monitoring. Largest and smallest diameters of the ASD, the areas of the
defect, sizing balloon and selected device waist were recorded as well as the char-
acteristics of the interatrial septum (IAS). BS with the PTS balloon was performed
using the "stop-ﬂow" technique. A Cera device (Lifetech, China) the same size of the
BS diameter or 1 mm larger was selected for implantation. Linear regression analyses
were employed to determine what was the best baseline parameter on 3D TEE to
predict adequate device selection. T tests or Mann-Whitney tests were used as
applicable.
Results: Twenty-ﬁve adult patients (mean age: 4215 years) were enrolled. Six had
redundant or aneurysmal IAS. In the entire cohort ASDs were oval measuring
19.66.5 X 14.24.5mm (p<0.001). The BS and selected device waist diameters
were 22.36.0 and 21.95.8 mm, respectively (p¼NS). The area of the ASD, sizing
balloon and device waist were 262.8144.7, 416.4  226.6, 402.2  196.9 mm2,
respectively (p¼NS between balloon and device areas). After device release waistJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrdiameter and area were 19.6  5.2mm (p¼NS) and a median of 281mm2 (73-677)
(p¼0.081), respectively, similar to pre-implantation values. In patients with thicker,
non-redundant IAS there was an excellent correlation between the largest ASD
diameter (R¼ 0,954; R2¼ 0,911) and the ASD area (R¼ 0,929; R2¼ 0,864) on 3D
TEE and the selected device diameter. A poor correlation was observed for patients
with redundant/aneurysmal IAS. The regression equations that were obtained for
proper device size selection were Device size (mm)¼ (Largest 3D TEE ASD diameter
X 0.888) + 3.911 mm and Device size (mm) ¼ 11,859 + (0,0374 X 3D TEE ASD
area).
Conclusions: The largest ASD diameter and the ASD area on 3D TEE were excellent
surrogates for BS in patients with thicker, non-redundant IAS. The application of this
new method for device selection may help to expedite the procedure and avoid
oversizing. These observations should be validated in prospective trials.
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Background: Endocarditis is a risk factor for and sequelae of surgical prosthetic
paravalvular leaks (PVLs). The modiﬁed Duke Criteria is the gold standard for
diagnosing infective endocarditis. Nonetheless, it has never been evaluated for pros-
thetic valve endocarditis (PVE). Concern remains regarding the safety of percutaneous
PVL closure in patients at high risk for PVE.
Methods: We evaluated patients from January 2012 to June 2013 who presented for
symptomatic PVL closure. High-risk for PVE was deﬁned as a modiﬁed Duke
Criteria that met at least 1 major and 1 minor criteria aside from a predisposing heart
condition. Gallium SPECT (24  48 hours) or PET imaging were fused with cardiac
CT. Patients with positive studies either underwent surgical valve replacement
(SVR) or 6 weeks of intravenous antibiotics followed by repeat nuclear study, with
subsequent intervention if resolved. Patient with negative studies underwent
percutaneous closure.
Results: 62 patients were evaluated with 11 patients deemed high risk for PVE
(6513 years, 100% heart failure, 37% hemolysis). Deﬁnite criteria were met in 27%
(2 major n¼2; 1 major 3 minor n¼1). Two patients had positive nuclear studies and
underwent SVR and 1 patient had a negative study and underwent SVR after
unsuccessful closure, with negative surgical cultures. Possible criteria were met in
72% (1 major 1 minor or 2 minor with echocardiogram concerning for abscess n¼2; 1
major 2 minor n¼6). 2 patients with abnormal echocardiograms had positive nuclear
studies and died (1 intraoperative with positive cultures, 1 inoperable). Two patients
had positive studies and successful closure after antibiotics and negative repeat
imaging. The remaining 4 patients had negative nuclear studies and successful closure.
On follow-up (8.58 months), no PVE was identiﬁed with improvement in NYHA by
1 and complete hemolysis resolution.
Conclusions: Early experience of Gallium SPECT/CT or PET/CT identiﬁes a poten-
tial role in the assessment of PVE in PVL patients. Further evaluation on the utility of
nuclear fusion imaging in this patient population is necessary.TCT-692
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Background: The WATCHMAN left atrial appendage (LAA) Closure Device has
been shown to be at least equivalent to anticoagulation for stroke prevention in
patients with non-valvular atrial ﬁbrillation (NVAF). A newer, (fourth) generation
WATCHMAN device (with a less traumatic distal tip and option of recapture and
redeployment) was designed to facilitate delivery and improve the safety proﬁle,
particularly the incidence of pericardial effusions. The aim of this study was to
evaluate the feasibility and safety of the newer (fourth) generation WATCHMAN left
atrial appendage (LAA) closure device.
Methods: This was a prospective, single-center, non-randomized study of LAA
closure in 36 patients with NVAF.
Results: Between February 2010 and June 2011, 36 patients (mean age: 72  16
years, male: 66.7%, median CHADS2 of 2.83, median CHA2DS2-VASc of 4.5)
with NVAF underwent percutaneous LAA closure with the newer (fourth)acts/POSTER/Non-valvular Structural Heart Disease B211
